A Multicenter, Open-Label, Randomized, Phase II/III Study to Evaluate the Safety and Efficacy of Combretastatin A-4 Phosphate in Combination with Paclitaxel and Carboplatin in comparison with Paclitaxel and Carboplatin against Anaplastic Thyroid Carcinoma - NA
Active, not recruiting
- Conditions
- Anaplastic thyroid carcinomaMedDRA version: 9.1Level: LLTClassification code 10043702Term: Thyroid carcinoma
- Registration Number
- EUCTR2007-002846-38-BG
- Lead Sponsor
- OXiGENE, Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 180
Inclusion Criteria
Anaplastic thyroid carcinoma histologically or cytologically confirmed pathology, having been refractory to or progressed during or after therapy
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range
Exclusion Criteria
Tumors confined to the thyroid or an uncontrolled active infection or clinically evident brain metastasis
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method